241 related articles for article (PubMed ID: 38803496)
1. Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.
Mantooth SM; Abdou Y; Saez-Ibañez AR; Upadhaya S; Zaharoff DA
Front Immunol; 2024; 15():1385484. PubMed ID: 38803496
[TBL] [Abstract][Full Text] [Related]
2. Advances in Combining Radiation and Immunotherapy in Breast Cancer.
Nguyen AT; Shiao SL; McArthur HL
Clin Breast Cancer; 2021 Apr; 21(2):143-152. PubMed ID: 33810972
[TBL] [Abstract][Full Text] [Related]
3. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer.
Chua CYX; Jain P; Susnjar A; Rhudy J; Folci M; Ballerini A; Gilbert A; Singh S; Bruno G; Filgueira CS; Yee C; Butler EB; Grattoni A
J Control Release; 2018 Sep; 285():23-34. PubMed ID: 30008369
[TBL] [Abstract][Full Text] [Related]
4. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
Zhou S; Cheng F; Zhang Y; Su T; Zhu G
Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Immunotherapy for Early-stage Solid Tumors.
Hong WX; Haebe S; Lee AS; Westphalen CB; Norton JA; Jiang W; Levy R
Clin Cancer Res; 2020 Jul; 26(13):3091-3099. PubMed ID: 32071116
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
7. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Liu HC; Viswanath DI; Pesaresi F; Xu Y; Zhang L; Di Trani N; Paez-Mayorga J; Hernandez N; Wang Y; Erm DR; Ho J; Susnjar A; Liu X; Demaria S; Chen SH; Teh BS; Butler EB; Xuan Chua CY; Grattoni A
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):492-506. PubMed ID: 32768562
[TBL] [Abstract][Full Text] [Related]
8. Emerging immunotherapeutic strategies for the treatment of breast cancer.
Huppert LA; Mariotti V; Chien AJ; Soliman HH
Breast Cancer Res Treat; 2022 Jan; 191(2):243-255. PubMed ID: 34716870
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral delivery of immune therapy and gene therapy: the next era for cancer therapy.
Wu VM; Arch RH; Canton DA; Zhang J
Immunotherapy; 2023 Aug; 15(11):853-865. PubMed ID: 37291871
[TBL] [Abstract][Full Text] [Related]
10. Image-guided intratumoral immunotherapy: Developing a clinically practical technology.
Som A; Rosenboom JG; Chandler A; Sheth RA; Wehrenberg-Klee E
Adv Drug Deliv Rev; 2022 Oct; 189():114505. PubMed ID: 36007674
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for breast cancer: past, present, and future.
Spellman A; Tang SC
Cancer Metastasis Rev; 2016 Dec; 35(4):525-546. PubMed ID: 27913998
[TBL] [Abstract][Full Text] [Related]
12. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
14. Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment.
Hope A; Wade SJ; Aghmesheh M; Vine KL
J Control Release; 2022 Jan; 341():399-413. PubMed ID: 34863842
[TBL] [Abstract][Full Text] [Related]
15. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer.
Mikhail AS; Morhard R; Mauda-Havakuk M; Kassin M; Arrichiello A; Wood BJ
Adv Drug Deliv Rev; 2023 Nov; 202():115083. PubMed ID: 37673217
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery.
Goldberg EP; Hadba AR; Almond BA; Marotta JS
J Pharm Pharmacol; 2002 Feb; 54(2):159-80. PubMed ID: 11848280
[TBL] [Abstract][Full Text] [Related]
18. An efficient or methodical review of immunotherapy against breast cancer.
Guanghui R; Xiaoyan H; Shuyi Y; Jun C; Guobin Q
J Biochem Mol Toxicol; 2019 Aug; 33(8):e22339. PubMed ID: 31157481
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral cancer immunotherapy exploiting anti-viral immunity.
Kadowaki N
J Clin Exp Hematop; 2022 Mar; 62(1):1-8. PubMed ID: 34707035
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
